Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAFA/LEN + R-CHOP for newly diagnosed intermediate-high-risk DLBCL
ChiCTR2600134208Phase 4Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tafasitamab, lenalidomide, rituximab, cyclophosphamide, doxorubicin and 2 more in diffuse large B-cell lymphoma (DLBCL), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: 2-year progression-free survival rate. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
tafasitamablenalidomiderituximabcyclophosphamidedoxorubicin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2600134208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134208.